The National Institute for Health and Care Excellence is backing routine NHS use of Amgen’s Kyprolis as an option for treating patients with multiple myeloma at first relapse. In a Final Appraisal Determination, the Institute has recommended the drug in combination with dexamethasone for adults with relapsed multiple myeloma (RMM) who have received one prior
Amgen have confirmed a new partnership with Servier to boost the pipelines of both businesses. The waiting period to let any antitrust concerns to arise has now passed, meaning the two companies can advance with the agreement. The deal will provide Amgen with rights in the US to Servier’s heart drug, ivabradine, which has already
Amgen has joined up with Bind Biosciences to develop a kinase inhibitor nanomedicine for treating a variety of solid tumours. The agreement provides the US biotech major with access to the technology at BIND, who has developed “a new class of highly selective targeted and programmable therapeutics,” which they call Accurins. The partners are planning
